Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LY3090106- SQ · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| LY3090106 (Healthy) | EXPERIMENTAL | Healthy participants will receive a single dose of LY3090106 in dose escalation cohorts subcutaneously (SQ). |
| Placebo (Healthy) | PLACEBO_COMPARATOR | Healthy participants will receive a single dose of placebo matching LY3090106 SQ. |
| LY3090106 (RA) | EXPERIMENTAL | Participants with RA will receive a single dose of LY3090106 in dose escalation cohorts SQ or intravenously (IV). |
| Placebo (RA) | PLACEBO_COMPARATOR | Participants with RA will receive a single dose of placebo matching LY3090106 SQ. |
| Name | Type | Description |
|---|---|---|
| LY3090106 - SQ | BIOLOGICAL | Administered SQ. |
| LY3090106 - IV | BIOLOGICAL | Administered IV. |
| Placebo - SQ | BIOLOGICAL | Administered SQ. |
Inclusion Criteria for Healthy Participants: * Males or non-pregnant females age 18 to 65 years * Body Mass Index (BMI) of 18.5 to 32.0 kilograms per meter squared (kg/m\^2) Inclusion Criteria for Participants for RA: * Diagnosis of at least mildly active adult-onset RA * Positive anti-citrullina...
Top 20 of 28 competitors
LY3090106 SQ is an investigational monoclonal antibody being studied for the treatment of rheumatoid arthritis. It is administered subcutaneously and is currently in Phase 1 clinical development. The drug is being evaluated in patients with rheumatoid arthritis as well as in healthy participants to assess its safety and tolerability.
LY3090106 SQ is being developed by Eli Lilly and Company, a biopharmaceutical company traded on the NYSE under the ticker symbol LLY. The company is conducting clinical research on this investigational monoclonal antibody for the treatment of rheumatoid arthritis.
LY3090106 SQ is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still being studied in clinical trials. The Phase 1 trial has been completed, and the drug remains under investigation for rheumatoid arthritis.
LY3090106 SQ has been studied in one clinical trial, identified as NCT01925157, titled "A Study of LY3090106 in Healthy Participants and Participants With Rheumatoid Arthritis (RA)." This Phase 1 trial was completed and enrolled 43 participants across Bulgaria, Moldova, Poland, and Romania.
LY3090106 SQ refers to the subcutaneous formulation of the investigational drug LY3090106. The SQ designation indicates the route of administration, which is subcutaneous injection. The drug is being developed by Eli Lilly and Company for the treatment of rheumatoid arthritis.